Over-expression of VEGF and MMP-9 in residual tumor cells of hepatocellular carcinoma after embolization with lipidol

Abstract

The expression and implication of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in residual hepatic tumor cells after lipiodol embolization were investigated. Two weeks after transplantation of VX2 tumor cells into the livers of rabbits, a xenograft model of the human hepatic neoplasm was successfully established. Forty rabbits were randomly divided into control group (n=20) and lipiodol group (n=20). For the control group, 1 mL normal saline was injected through the gastroduodenal artery, whereas 0.3 mL/kg lipiodol was applied for the lipiodol group. One week after embolization, the expression level of VEGF in the plasma was measured by using enzyme-linked immunosorbent assay (ELISA). A three-step immunohistochemical technique (ABC) was employed to detect the protein levels of VEGF and MMP-9 and the quantitative PCR for their mRNA levels was performed in the residual tumor cells. The VEGF in the plasma was significantly higher in the lipiodol group (1.42±0.29 ng/mL) than in the control group (1.12±0.21 ng/mL) (P<0.01). Moreover, the positive rate of VEGF protein in the residual tumor cells was significantly higher in the lipiodol group (62.13%±7.69%) than in the control group (53.16%±9.17%) (P<0.05). Similarly, the MMP-9 expression in the residual tumor cells was higher in the lipiodol group. The mRNA levels of VEGF (2.9313±2.4231) and MMP-9 (3.5721±1.6107) in the lipiodol group were significantly higher than those in the control group (1.5728±0.9453 and 1.7573±1.0641, respectively, P<0.05). Therefore, it was reasonable to speculate that the increased expression of VEGF and MMP-9 in residual hepatic tumor cells and tumor angiogenesis post-embolization would be responsible for the increased metastatic potentiality and invasiveness of these cells.

Keywords

vascular endothelial growth factor / matrix metalloproteinase-9 / embolization / residual hepatic tumor cells / metastasis

References

[1] SemelaD., HeimM.. Hepatocellular carcinoma. Ther Umsch, 2011, 68(4): 213-217

[2] TakavasuK., AriiS., IkaiI., et al.. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology, 2006, 131(2): 461-469

[3] SongM.J., ParkC.H., KimJ.D., et al.. Drug-eluting bead loaded with doxorubicin versus conventional lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol, 2011, 23(6): 521-527

[4] OkabeK., BeppuT., HaraokaK., et al.. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma. Anticancer Res, 2011, 31(9): 2983-2988

[5] SergioA., CristoforiC., CardinR., et al.. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol, 2008, 103(4): 914-921

[6] MareelM., ConstantinoS.. Ecosystems of invasion and metastasis in mammary morphogenesis and cancer. Int J Dev Biol, 2011, 55(7–9): 671-684

[7] WeisS.M., ChereshD.A.. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med, 2011, 17(11): 1359-1370

[8] ShenY.C., HsuC., ChengA.L.. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol, 2010, 45(8): 794-807

[9] ChenL., ShiY., JiangC.Y., et al.. Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. Int J Biol Markers, 2011, 26(2): 108-116

[10] SulluY., DemiragG.G., YildirimA., et al.. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. 2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract, 2011, 207(12): 747-753

[11] XiangZ.L., ZengZ.C., FanJ., et al.. Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res, 2011, 17(16): 5463-5472

[12] BauschD., PauschT., KraussT., et al.. Neutrophil granulocyte-derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis, 2011, 14(3): 235-243

[13] GuT., LiC.X., FengY., et al.. Trans-arterial gene therapy for hepatocellular carcinoma in a rabbit model. World J Gastroenterol, 2007, 13(14): 2113-2117

[14] KeS., DingX.M., KongJ., et al.. Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma. J Transl Med, 2010, 8: 73-83

[15] XuT., ChenX.P., LiD., et al.. Expression of EMMPRIN in rabbit VX2 liver tumor tissue and significance. Zhonghua Shiyan Waike Zazi (Chinese), 2007, 24(1): 37-39

[16] XuT., ChenX.P., GuoY.X., et al.. Expression of MT1-MMP and its significance in rabbit VX2 tumor tissues after transarterial embolization with hydroxyapatite nanoparticles. Zhonghua Waike Zazi (Chinese), 2008, 46(8): 606-609

[17] ByrneA.M., Bouchier-HayesD.J., HarmeyJ.H.. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med, 2005, 9(4): 777-794

[18] CarmelietP.. VEGF as a key mediator of angiogenesis in cancer. Oncology, 2005, 69(3): 4-10

[19] ChenY., JiangL., SheF., et al.. Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism. Mol Cell Biochem, 2010, 345(1–2): 77-89

[20] KolevY., UetakeH., IidaS., et al.. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol, 2007, 14(10): 2738-2747

[21] ZhuA.X., DudaD.G., SahaniD.V., et al.. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol, 2011, 8(5): 292-301

[22] HuangX., HuangS., ZhangF., et al.. Lentiviral-mediated Smad4 RNAi promotes SMMC-7721 cell migration by regulation of MMP-2, VEGF and MAPK signaling. Mol Med Report, 2010, 3(2): 295-299

[23] OrlichenkoL.S., RadiskyD.C.. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis, 2008, 25(6): 593-600

[24] MorrisonC., ManciniS., CipolloneJ., et al.. Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis. J Biol Chem, 2011, 286(39): 34 271-34 285

[25] GolubkovV.S., ChekanovA.V., SavinovA.Y., et al.. Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells. Cancer Res, 2006, 66(21): 10 460-10 465

[26] HuF., WangC., GuoS., et al.. δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Biochim Biophys Acta, 2011, 1809(3): 200-210

[27] ZhangW., YangH.C., WangQ., et al.. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res, 2011, 31(10): 3423-3428

[28] der JagtM.F., WobbesT., StrobbeL.J., et al.. Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol, 2010, 101(3): 259-269

[29] BendardafR., BuhmeidaA., HilskaM., et al.. MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest, 2010, 28(1): 38-43

[30] ChenJ.S., WangQ., FuX.H., et al.. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res, 2009, 39(2): 177-186

[31] SaharinenP., EklundL., PulkkiK., et al.. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med, 2011, 17(7): 347-362

[32] Van HinsberghV.W., EaglseM.A., QuaxP.H.. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol, 2006, 26(4): 716-728

[33] TsaiM.Y., YangR.C., WuH.T., et al.. Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascu lar endothelial cells. Cancer Lett, 2011, 310(2): 198-206

[34] KimC.H., LeeJ.H., WonJ.H., et al.. Mesenchymal stem cells improve wound healing in vivo via early activation of matrix metalloproteinase-9 and vascular endothelial growth factor. J Korean Med Sci, 2011, 26(6): 726-733

[35] OrtegaN., WangK., FerraraN., et al.. Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation. Dis Model Mech, 2010, 3(3–4): 224-235

[36] YangP., YuanW., HeJ., et al.. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol Res, 2009, 39(12): 1169-1177

[37] ManK., NgK.T., XuA., et al.. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res, 2010, 16(3): 967-977

[38] HouY.K., WangY., CongW.M., et al.. Expression of tumor metastasis-suppressor gene KiSS-1 and matrix metalloproteinase-9 in portal vein tumor thrombus of hepatocellular carcinoma. Ai Zheng, 2007, 26(6): 591-595

[39] ZhangQ., ChenX., ZhouJ., et al.. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther, 2006, 5(7): 808-814

[40] TakavasuK., AriiS., IkaiI., et al.. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology, 2006, 131(2): 461-469

[41] LiapiE., GeorgiadesC.C., HongK., et al.. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol, 2007, 10(1): 2-11

[42] WangB., XuH., GaoZ.Q., et al.. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol, 2008, 49(5): 523-529

[43] ShimJ.H., ParkJ.W., KimJ.H., et al.. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci, 2008, 99(10): 2037-2044

[44] RheeT.K., YoungJ.Y., LarsonA.C., et al.. Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1alpha in rabbit VX2 liver tumors. J Vasc Interv Radiol, 2011, 18(5): 639-645

[45] DengG., ZhaoD.L., LiG.C., et al.. Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor. Cardiovasc Intervent Radiol, 2011, 34(4): 824-832

[46] JananiP., SivakumariK., GeethaA., et al.. Bacoside A downregulates matrix metalloproteinases 2 and 9 in DEN-induced hepatocellular carcinoma. Cell Biochem Funct, 2010, 28(2): 164-169